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Abstract
Background: Chronic treatment with selective serotonin (5-HT) reuptake inhibitors (SSRIs) facilitates adult
neurogenesis and reverses the state of maturation in mature granule cells (GCs) in the dentate gyrus (DG) of the
hippocampus. Recent studies have suggested that the 5-HT4 receptor is involved in both effects. However, it is
largely unknown how the 5-HT4 receptor mediates neurogenic effects in the DG and, how the neurogenic and
dematuration effects of SSRIs interact with each other.
Results: We addressed these issues using 5-HT4 receptor knockout (5-HT4R KO) mice. Expression of the 5-HT4
receptor was detected in mature GCs but not in neuronal progenitors of the DG. We found that chronic treatment
with the SSRI fluoxetine significantly increased cell proliferation and the number of doublecortin-positive cells in the
DG of wild-type mice, but not in 5-HT4R KO mice. We then examined the correlation between the increased
neurogenesis and the dematuration of GCs. As reported previously, reduced expression of calbindin in the
DG, as an index of dematuration, by chronic fluoxetine treatment was observed in wild-type mice but not in
5-HT4R KO mice. The proliferative effect of fluoxetine was inversely correlated with the expression level of calbindin
in the DG. The expression of neurogenic factors in the DG, such as brain derived neurotrophic factor (Bdnf),
was also associated with the progression of dematuration. These results indicate that the neurogenic effects of
fluoxetine in the DG are closely associated with the progression of dematuration of GCs. In contrast, the DG in
which neurogenesis was impaired by irradiation still showed significant reduction of calbindin expression by
chronic fluoxetine treatment, suggesting that dematuration of GCs by fluoxetine does not require adult neurogenesis
in the DG.
Conclusions: We demonstrated that the 5-HT4 receptor plays an important role in fluoxetine-induced adult
neurogenesis in the DG in addition to GC dematuration, and that these phenomena are closely associated.
Our results suggest that 5-HT4 receptor-mediated phenotypic changes, including dematuration in mature
GCs, underlie the neurogenic effect of SSRIs in the DG, providing new insight into the cellular mechanisms
of the neurogenic actions of SSRIs in the hippocampus.
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Background
Chronic antidepressant administration increases adult
neurogenesis in the dentate gyrus (DG) of the hippo-
campus [1,2], which is thought to contribute, in part, to
antidepressant activity in rodent behavioral models [3].
Antidepressants also regulate the expression of various
genes, such as those encoding neurotrophic factors, in
the DG [4,5], which is important for behavioral and
neurogenic actions of antidepressants in the DG [6].
Among antidepressants, selective serotonin (5-HT) re-
uptake inhibitors (SSRIs) including fluoxetine specifically
increase synaptic 5-HT levels. 5-HT receptors are subdi-
vided into 14 subtypes in rodents [7]; results of recent
pharmacological studies have suggested that in addition
to the 5-HT1A receptor [3], the 5-HT4 receptor [8,9] me-
diates SSRI-induced neurogenic actions in the DG. It
has been reported that 5-HT4 receptor agonists such as
RS67333 show antidepressant-like behavioral effects in
the forced swim test and sucrose consumption test, and
enhance neurogenic activity in the DG in rats [8]. A re-
cent study also showed that the 5-HT4 receptor antag-
onist GR125487 partially prevents the neurogenic effects
of fluoxetine in a mouse model of anxiety and depres-
sion [9]. However, it is still largely unknown how the
5-HT4 receptor mediates the neurogenic effect of
SSRIs in the DG.
We have recently shown that chronic treatment with
fluoxetine transforms mature granule cells (GCs) to an
immature-like state in the DG in a so-called “dematura-
tion” process, and that the 5-HT4 receptor is essential
for this change [10]. Dematured GCs exhibit reduced ex-
pression of mature GC markers including calbindin,
increased somatic excitability, and reduced activity-
dependent synaptic facilitation. Chronic fluoxetine treat-
ment also induces marked enhancement of 5-HT- and
dopamine-induced synaptic potentiation at the mossy fiber
synapse, the sole output of the GCs [10,11]. These findings
give rise to questions regarding the mechanism through
which the 5-HT4 receptor contributes to both neurogenic
and dematuration effects of chronic SSRI administration
within the DG and regarding the association between these
cellular and phenotypic changes in the DG.
In this study, we address these issues in 5-HT4 recep-
tor knockout (5-HT4 KO) mice with the C57BL/6 J
background. We demonstrate that the 5-HT4 receptor
plays an important role in both fluoxetine-induced adult
neurogenesis and GC dematuration in the DG, and that
these phenomena are closely associated with each other.
Results
Requirement of the 5-HT4 receptor for fluoxetine-induced
neurogenic effects in the DG
Pharmacological studies using 5-HT4 receptor agonists
and antagonists have suggested that the 5-HT4 receptor
is involved in the adult neurogenesis of the DG [8,9].
However, there is no study examining the influence of
genetic deficiency of the 5-HT4 receptor on SSRI-
induced neurogenesis in the DG. In this study, we exam-
ined the effect of SSRI treatments on adult neurogenesis
in 5-HT4R KO mice with the C57BL/6 J background, in
which we have previously demonstrated the involvement
of the 5-HT4 receptor in the fluoxetine-induced dema-
turation of GCs.
Because it has been reported that the 5-HT content
in the raphe nuclei is decreased in a distinct line of 5-
HT4R KO mice with the 129/Sv background [12], we
first measured the contents of 5-HT and its main metab-
olite, 5-hydroxyindole acetic acid (5-HIAA), in the
hippocampus and the raphe nuclei in 5-HT4R KO mice
with the C57BL/6 J background. The contents of 5-HT
and 5-HIAA in both the hippocampus and the raphe nu-
clei were similar between wild-type (WT) and 5-HT4R
KO mice (Figure 1A). We also examined the increase in
extracellular 5-HT accumulation after a single adminis-
tration of fluoxetine by in vivo microdialysis assays
(Figure 1B). Intraperitoneal injection of fluoxetine
caused a significantly larger increase in hippocampal 5-
HT levels than vehicle injection. The increase in 5-HT
levels after administration of fluoxetine was not signifi-
cantly different between genotypes.
We further examined the contents of 5-HT and 5-
HIAA in the hippocampus after chronic fluoxetine treat-
ment. Consistent with a previous report [13], chronic
fluoxetine treatment significantly reduced the total con-
tents of 5-HT and 5-HIAA in the hippocampus, which is
considered to reflect feedback inhibition of 5-HT bio-
synthesis in the raphe nucleus. We found that the 5-HT
content after chronic fluoxetine treatment were not sig-
nificantly different between WT and 5-HT4R KO mice
(Figure 1C). Therefore, we used this mutant line to
address the involvement of the 5-HT4 receptor in SSRI-
induced neurogenic activity in the DG. However,
because the main effect of genotype for 5-HIAA was
significant, we could not exclude the possibility that dif-
ferences in 5-HT metabolism might lead to a higher
amount of 5-HIAA in 5-HT4R KO mice to WT mice.
Mice were intraperitoneally treated with 22 mg/kg
fluoxetine for 21 days (from day-1 to day-21), and 5-
bromodeoxyuridine (BrdU) was given 2 h before sacri-
fice on day-22 to label proliferating cells (Figure 2A).
Chronic fluoxetine treatment significantly increased the
number of BrdU-positive cells in the subgranular zone
(SGZ) of the DG compared with saline treatment in WT
mice, whereas no significant difference was observed be-
tween saline and fluoxetine treatments in 5-HT4R KO
mice (Figure 2B and C). We next assessed the number
of immature neurons by immunostaining for doublecor-
tin (DCX), a marker of neurogenesis (Figure. 2D and E).
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The number of DCX-positive cells in the DG was signifi-
cantly increased in fluoxetine-treated WT mice, whereas
no significant difference was observed between saline
and fluoxetine treatments in 5-HT4R KO mice. These
results demonstrate that the 5-HT4 receptor is import-
ant for the neurogenic effect of chronic fluoxetine treat-
ment in the DG.
The 5-HT4 receptor is expressed in the mature GCs of
the DG
It has been reported that the 5-HT4 receptor is abun-
dantly expressed in the DG [14,15]. As reported previ-
ously, we observed that 5-HT4 receptor mRNA (Htr4)
is mainly expressed in the granule cell layer, rather
than in the SGZ, of the DG by in situ hybridization
(Figure 3A). The expression level of Htr4 in the DG
was not significantly changed by chronic fluoxetine
treatment (control, 1.000 ± 0.091; fluoxetine, 1.348 ± 0.152;
[fold change], P = 0.079, unpaired Student’s t-test;
assessed by quantitative reverse transcription (RT)-PCR;
n = 6 each). To determine the cell types expressing
the 5-HT4 receptor in the DG, we examined β-
galactosidase immunoreactivity (LacZ-IR) in the
hippocampus of the 5-HT4R KO mice, in which the
β-galactosidase gene was ‘knocked-in’ at the Htr4
gene locus. We found that the LacZ-IR was co-
localized with the immunoreactivity of a neural
marker, NeuN, and that of a marker for mature GCs,
calbindin. However, they were not co-localized with
the immunoreactivity of DCX, a marker of neural pro-
genitors and immature neurons, and that of calretinin, a
marker of immature GCs, in the SGZ (Figure 3B), sug-
gesting that the 5-HT4 receptor is mainly expressed in
mature GCs.
Figure 1 5-HT levels in the hippocampus of 5-HT4R KO mice with the C57BL/6 J-background. (A) Tissue 5-HT and 5-HIAA levels in the hippocampus
and raphe nuclei. Data are expressed as the mean ± SEM (n = 7 or 8). N.S., not significant for unpaired t-tests. (B) Fluoxetine (Flx)-induced increase in
extracellular 5-HT concentrations in the hippocampus. After equilibration, dialysate samples were collected every 20 min with either fluoxetine
(22 mg/kg) or saline (Sal) administered at time zero. The average value of seven basal samples for each animal was defined as 100% and used
for normalization. Data are expressed as the mean ± SEM (n = 4 for fluoxetine, n = 3 for saline). Main effect of group: P = 0.0499; main effect of
time point: P < 0.0001; interaction of group and time point: P < 0.0001. P value was determined by two-way ANOVA for repeated measures.
* P < 0.01 [WT(Sal) vs WT(Flx)] for post hoc Bonferroni’s test after two-way ANOVA; N.S, not significant [WT(Flx) vs KO(Flx)] for post hoc Bonferroni’s
test at every time point after two-way ANOVA. (C) Tissue 5-HT and 5-HIAA levels in the hippocampus after chronic fluoxetine treatment. Fluoxetine
(22 mg/kg) was administered for 3 weeks. Data are expressed as the mean ± SEM (n = 7 or 8). Main effect of drug: #P < 0.0001 (5-HT), #P < 0.0001
(5-HIAA); main effect of genotype: P = 0.9734 (5-HT), P = 0.0423 (5-HIAA); interaction of drug and genotype: P = 0.9790 (5-HT), P = 0.3243 (5-HIAA);
P values determined by two-way ANOVA.
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The neurogenic effect of fluoxetine is correlated with
dematuration of GCs in the DG
We previously reported that the 5-HT4 receptor is
necessary for fluoxetine-induced dematuration in GCs
[10]. Dematured GCs exhibit various phenotypic
changes including reduced expression of mature GC
markers, increased somatic excitability, and reduced
activity-dependent synaptic facilitation. Because the
expression of the 5-HT4 receptor in the DG is mainly
localized to mature GCs, we hypothesized that the pro-
gression of GC dematuration via the 5-HT4 receptor is
correlated with the neurogenic effect of fluoxetine within
the SGZ of the DG. To evaluate the phenotypic changes
related to GC dematuration, the reduction in the expres-
sion level of the mature GC marker calbindin was used
as an index of dematuration of GCs [10]. Chronic
fluoxetine treatment significantly reduced calbindin-IR
in both the granule cell layer and molecular layer of
the DG in WT mice, but not in 5-HT4R KO mice
(Figure 4A and B). To examine the correlation between
the proliferative and dematuration-inducing effects of
fluoxetine, we compared the number of BrdU-positive
cells and the calbindin-IR in the DG of the same animal,
and found that the number of proliferating cells was
closely and inversely associated with the calbindin-IR in
the granule cell layer (GCL) (Figure 4C). It is known that
antidepressant treatment increases the expression of
growth factors and neuropeptides including Bdnf and
neuropeptide Y (Npy) in the DG [4,5], which are sug-
gested to be involved in the enhanced neurogenesis
[16-18]. We also examined the correlation between
the increased expression of these factors and reduced
Figure 2 Effect of chronic fluoxetine treatment on adult neurogenesis in 5-HT4R KO mice. (A) Experimental scheme. Mice were intraperitoneally
(ip) injected with fluoxetine (Flx) at a dose of 22 mg/kg for 21 days and were administered BrdU 24 h after the last treatment (on day-22) at a
dose of 150 mg/kg. Mice were sacrificed 2 h after the BrdU injection. (B) Immunohistochemical visualization of BrdU in the SGZ of the DG. Scale
bar: 100 μm. Arrows represent BrdU-positive cells. (C) Quantification of BrdU-positive cells in the SGZ of the DG in WT mice and 5-HT4R KO mice.
Data are expressed as the mean ± SEM (n = 4 or 5). Main effect of drug: P = 0.0023; main effect of genotype: P = 0.0107; interaction of drug and
genotype: P = 0.0048; P values determined by two-way ANOVA. *** P < 0.001 and N.S, not significant for post hoc Bonferroni’s test, respectively,
after two-way ANOVA. (D) Representative images of anti-doublecortin (DCX) immunohistochemistry in the DG. Scale bar: 100 μm. (E) Quantification of
DCX-positive immature neurons in the DG of the WT mice and 5-HT4R KO mice. The number of DCX-positive cells in the DG is shown as the number
of cells per square millimeter of DG area. Data are expressed as the mean ± SEM (n = 4 or 5). Main effect of drug: P = 0.0214; main effect of genotype:
P = 0.1372; interaction of drug and genotype: P = 0.0032; P values determined by two-way ANOVA. ** P < 0.01 and N.S., not significant for post hoc
Bonferroni’s test, respectively, after two-way ANOVA.
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calbindin mRNA (Calb1) in the individual fluoxetine-
treated DG (as compared to average control DG mRNA
levels); the expression changes, as determined by quanti-
tative RT-PCR, were inversely correlated (Figure 4D).
The combined observation of inverse correlations be-
tween the intensity of calbindin-IR and cell proliferation,
along with the expression of neurogenic factors, respect-
ively, suggest that the neurogenic effect of fluoxetine in
the SGZ is closely associated with the progression of GC
dematuration in the DG.
Dematuration of GCs by chronic fluoxetine treatment still
occurs without adult neurogenesis
We next examined whether adult neurogenesis affects
the dematuration of GCs by fluoxetine. To address this
point, we used X-ray irradiation to block the production
of new neurons within the SGZ, and examined the effect
of fluoxetine on the reduction of calbindin-IR in
the neurogenesis-depleted DG. Mice were irradiated
with X-rays directed at the whole cranium 14 days be-
fore initiation of the fluoxetine treatment (Figure 5A).
We confirmed that X-ray irradiation dramatically de-
pleted the DCX-positive cells in the DG of both saline-
and fluoxetine-treated mice (Figure 5B). Irradiation by
X-rays had no effect on calbindin-IR in saline-treated
mice (Figure 5C and D). Compared to saline, chronic
fluoxetine treatment also reduced calbindin-IR in X-ray-
irradiated mice (Figure 5C and D). These results suggest
that neurogenesis is not a critical factor for the dema-
turation of GCs by fluoxetine treatment.
Discussion
We have previously shown that chronic SSRI treatment
reverses the mature phenotype of GCs to an immature
like-state, called dematuration, via the 5-HT4 receptor
[10]. In this study, we demonstrated that the 5-HT4 re-
ceptor plays an important role in the fluoxetine-induced
increases in both cell proliferation and DCX-positive
cells in the DG. This increase in DCX-positive cells may
be due to either the development of additional neuronal
progenitors or the dematuration of mature GCs. We also
demonstrated that fluoxetine-induced increases in cell
proliferation and the expression of neurogenic factors in
the DG are closely associated with the progression of
GC dematuration (Figure 6).
Involvement of 5-HT receptors in the neurogenic effect
of fluoxetine
Previous reports showed that 5-HT receptor subtypes
other than the 5-HT4 receptor contribute to the effect of
chronic fluoxetine treatment in the DG. One candidate
is the 5-HT1A receptor. 5-HT1A receptor KO mice did
not exhibit cell-proliferating effects of SSRI treatment
[3]. Although it is known that desensitization of the
5-HT1A autoreceptor in serotonergic neurons after
chronic SSRI treatment is a key factor in enhanced
serotonergic synaptic transmission, the role of the 5-HT1A
receptor in the hippocampus has also been suggested to
be necessary for antidepressant responses. The 5-HT1A
receptor is abundantly expressed in the DG [14], and its
activation increases cell proliferation in the DG even in
the 5-HT-depleted rats [19]. These studies suggest that
Figure 3 Expression of the 5-HT4 receptor in the DG. (A) in situ
hybridization analysis of 5-HT4 receptor mRNA expression. GCL:
granular cell layer, SGZ: subgranular zone. Scale bars: 100 μm (left)
and 30 μm (right). (B) Representative images of β-galactosidase
(LacZ) and markers of granule cells; NeuN, calbindin, doublecortin
(DCX), and calretinin. Scale bar: 20 μm. Arrows represent DCX-positive
cells. Arrow heads represent calretinin-positive cells.
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the 5-HT1A receptor is involved in neurogenesis mediated
by SSRIs. However, it was recently reported that 8-OH-
DPAT—a 5-HT1A receptor agonist—did not increase cell
proliferation in the DG in the C57BL/6 mice [20]. This
suggests that the involvement of the 5-HT1A receptor in
neurogenesis may be different among species and stains
and that the contribution of the 5-HT4 receptor to SSRI-
enhanced neurogenesis may be more prominent in the
C57BL/6 strain.
Similarly, there are two possible pathways mediating
the 5-HT4 receptor action in the neurogenic effects of
fluoxetine: regulating the activity of serotonergic neu-
rons and activating the neurogenic signals in hippocam-
pus. It has been reported that the activity of serotonergic
neurons in the dorsal raphe nuclei is increased by 5-HT4
receptor activation [21]. In fact, the 5-HT level is re-
duced in the dorsal raphe nuclei in 5-HT4R KO mice of
the 129/Sv background [12]. However, the present study
showed that 5-HT and 5-HIAA tissue contents, in
addition to extracellular 5-HT accumulation induced by
fluoxetine in the hippocampus, were not different be-
tween WT and 5-HT4R KO mice of the C57BL/6 J back-
ground (Figure 1). This result indicates that the deficits
of cellular responses in the DG to fluoxetine in 5-HT4R
KO mice described in this study were not due to a
change in 5-HT level. However, we cannot exclude the
possibility that the activity of serotonergic neurons in
the dorsal raphe nuclei is regulated by the 5-HT4
Figure 4 Correlation between enhancement of adult neurogenesis and dematuration of GCs. (A) Representative images of calbindin-IR. GCL:
granule cell layer, ML: molecular layer. Scale bar: 100 μm. (B) Quantification of calbindin-IR in the GCL and the ML in WT mice and 5-HT4R KO
mice. Data are expressed as the mean ± SEM (n = 4 or 5). Main effect of drug: P = 0.0014 (GCL), P = 0.0015 (ML); main effect of genotype: P = 0.0237
(GCL), P = 0.0208 (ML); interaction of drug and genotype: P = 0.0022 (GCL), P = 0.0009 (ML); P values determined by two-way ANOVA. *** P < 0.001 and
N.S., not significant for post hoc Bonferroni’s test, respectively, after two-way ANOVA. (C) Comparison between the number of BrdU-positive cells in the
SGZ and calbindin-IR intensity of the granule cell layer in WT mice. Mice that received fluoxetine treatment (22 mg/kg) for 3 or 4 weeks were plotted in
the analysis. The Pearson correlation coefficient (R) was calculated (P = 0.0278). (D) Comparison of gene expression changes after chronic fluoxetine
treatment between calbindin (Calb1) and Bdnf or Npy. Gene expression was normalized by the average gene expression in control mice. Mice received
fluoxetine treatment (22 mg/kg) for 3 or 4 weeks. Four independent experiments were included in the analysis. The Pearson correlation coefficient (R)
was calculated (Bdnf vs. Calb1, P = 0.0002, Npy vs. Calb1, P < 0.0001).
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receptor in a manner that does not depend on 5-HT
levels in the hippocampus.
Interaction between increased neurogenesis and
dematuration of GCs in the DG
In this study, we showed that the neurogenic effect of
fluoxetine in the DG is closely associated with the pro-
gression of GC dematuration in the same animals
(Figure 4). This association is supported by the fact that
fluoxetine-induced neurogenesis and GC dematuration
showed a similar dose and time dependency in C57BL/6
background mice [10,22,23], and both effects of flu-
oxetine were augmented by chronic corticosterone
administration, a model of the anxiety and depressive-
like state [24,25]. In addition, alpha-calcium/calmodulin-
dependent protein kinase II (α-CaMKII) heterozygous
KO mice, Shunurri-2 KO mice, and pilocarpine-treated
mice also exhibited enhanced adult neurogenesis concur-
rently with immaturity of the GCs [26-28], showing the
correlation of the two adjacent cellular changes in other
cases. Given the 5-HT4 receptor expression in mature
GCs (Figure 3) and its requirement for not only GC
dematuration but also increase in neurogenesis by fluox-
etine (Figures 2 and 4), it is possible that dematuration-
related phenotypic changes via the 5-HT4 receptor in
mature GCs are involved in the increase in adult neuro-
genesis in the DG. Another possibility, however, is
that chronic fluoxetine treatment affects unidentified
factors via the 5-HT4 receptor; thus, additional mecha-
nisms could independently regulate neurogenesis and
dematuration-related phenotypic changes in the DG.
We also showed that the reduction of calbindin ex-
pression by chronic fluoxetine treatment was observed
in the absence of newly-generated neurons in the DG
Figure 5 Effect of X-ray irradiation on fluoxetine-induced adult neurogenesis and dematuration in the DG. (A) Experimental scheme. Mice were
irradiated with X-rays (10 Gy) 14 days before initiation of fluoxetine treatment (ip, intraperitoneally injected). Mice were sacrificed 24 h after the
final drug treatment. (B and C) Representative images of DCX (B) and calbindin (C) immunohistochemistry. Scale bars: 100 μm. (D) Quantification
of calbindin-IR signal intensity in the GCL and the ML in control (Sham) and X-ray-irradiated mice. Data are expressed as the mean ± SEM (n =5 or 6).
Main effect of drug: P < 0.0001 (GCL), P < 0.0001 (ML); main effect of X-ray irradiation: P = 0.0303 (GCL), P = 0.0087 (ML); interaction of drug and X-ray
irradiation: P = 0.1089 (GCL), P = 0.2085 (ML); P values determined by two-way ANOVA.
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(Figure 5). This result indicates that adult neurogenesis
is not necessary for the induction of GC dematuration.
However, it is noteworthy that the GC dematuration by
fluoxetine was slightly attenuated in the irradiated mice
compared with sham-treated mice. It has been reported
that adult-born GCs modify the excitability of pre-
existing mature GCs [29]. Although other effects of
X-ray irradiation, such as inflammation, must be con-
sidered, it is possible that newly-generated neurons
may contribute to the progression or maintenance of
dematuration of GCs in a positive-feedback manner.
How can the phenotypic changes including dematura-
tion of GCs enhance adult neurogenesis in the DG? One
possibility is that there is an increase in the expression
of neurogenic factors in the DG during dematuration.
We showed that Bdnf and Npy expression in the DG is
increased by chronic fluoxetine treatment, and that this
increased expression is correlated with the progression
of GC dematuration (Figure 4). The dematured state of
GCs may persistently activate signaling pathways to in-
crease the expression of these neurogenic factors. In
support of this hypothesis, central NPY and BDNF
administration was found to promote hippocampal
neurogenesis [16,18]. It has been reported that defi-
ciency or blockade of the BDNF receptor tropomyosin
receptor kinase B (TrkB) prevents fluoxetine-mediated
stimulation of mitosis in progenitor cells [17,30], sug-
gesting the involvement of this signal in the neurogenic
effect of fluoxetine. Thus, the increased expression of
these neurogenic factors in the dematured DG is likely
to mediate the enhancement of adult neurogenesis.
One other possibility is that an alteration occurs in the
microcircuits of the hippocampus. Dematured GCs ex-
hibit a lower threshold for action potentials, in addition
to enhancement of monoamine-induced synaptic po-
tentiation at the mossy fiber synapse [10,11]. Given that
parvalbumin-positive GABAergic interneurons in the
DG receive excitatory input from GCs [31], dematured
GCs could affect the functions of these GABAergic
interneurons in the DG. It has been reported that
GABAergic signals from parvalbumin interneurons dir-
ectly stimulate neural progenitors and modulate adult
neurogenesis in the SGZ [32,33]. Therefore, dematured
GCs may modulate adult neurogenesis via GABAergic
signals in the DG.
Behavioral effects of SSRI-induced dematuration of GCs in
the DG
In this study, we suggest that dematuration and other
phenotypic changes in GCs by chronic SSRI treatments
may act upstream of increased neurogenesis. Therefore,
it is expected that the associated phenotypic changes of
GCs indirectly regulate the neurogenesis-dependent
behavioral changes caused by chronic SSRI treatment.
Mature GCs constitute the majority of the neuronal
population in the DG and regulate hippocampal func-
tions. Therefore, in addition to having an influence on
neurogenesis-dependent functions, the dematuration
of mature GCs is assumed to have a significant im-
pact on both hippocampus-related and neurogenesis-
independent behaviors. Recent reports showed that
antidepressant-like behaviors resulting from chronic
fluoxetine treatment were mediated by both X-ray-
sensitive and -insensitive processes [9,24]. We showed
that X-ray irradiation blocked adult neurogenesis, but
spared the process of dematuration in GCs after chronic
fluoxetine treatment (Figure 5); it is therefore likely that
the behaviors blocked by X-ray irradiation are closely as-
sociated with neurogenesis. Our results additionally sug-
gest that dematuration of GCs may contribute to X-ray
insensitive antidepressant-like behaviors. However, we
also observed that X-ray irradiation tends to attenuate
the process of dematuration in GCs by fluoxetine treat-
ment. Thus, caution should be exercised in interpreting
the occurrence of X-ray-sensitive behaviors. We have
previously reported that chronic fluoxetine treatment in-
duced behavioral destabilization of home cage behaviors,
which instability was attenuated in 5-HT4R KO mice
[34]. Because a deficiency in 5-HT4 receptors abolished
both the neurogenic and dematuration effects of fluoxet-
ine in the DG, it is difficult to interpret which cellular
changes contribute to the behavioral changes that occur
in 5-HT4R KO mice. Comparison of the behavioral
Figure 6 Model of 5-HT4 receptor-mediated increased neurogenesis
and GC dematuration in the DG induced by chronic SSRIs. Chronic
SSRI treatment induces dematuration of GCs and increases adult
neurogensis via the 5-HT4 receptor (5-HT4R) in the DG. Dematured
GCs exhibit an increase in expression of neurogenic factors, which
may be involved in enhanced adult neurogenesis in the SGZ of
the DG.
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effects of fluoxetine between WT mice and 5-HT4R KO
mice under during the blockade of adult neurogenesis by
X-ray will be performed in a future study to clarify the
implications of GC dematuration-associated behaviors.
Conclusions
We demonstrated that the 5-HT4 receptor plays an im-
portant role in fluoxetine-induced adult neurogenesis in
the DG in addition to the dematuration of GCs, and that
these phenomena are closely associated. The present study
suggests that chronic fluoxetine treatment induces dema-
turation of GCs, which in turn increases neurogenesis. An
alternate possibility is that chronic fluoxetine treatment
affects unidentified factors via the 5-HT4 receptor, which
independently regulate neurogenesis and dematuration-
related phenotypic changes in the DG. Our study provides
new insights into the cellular mechanisms of adult neuro-
genesis induced by antidepressant treatment.
Methods
Animals
All mice were housed under standard illumination
parameters with a 12-h light/dark cycle and ad libitum
access to water and food. Male 5-HT4 receptor heterozy-
gous mutant mice that had been backcrossed to the
C57BL/6 J background for 10 generations were pur-
chased from the Jackson Laboratory (Bar Harbor, ME,
USA). Male (6–12 weeks old) wild-type (WT) and
homozygous mutant (5HT4R KO) mice prepared by
heterozygous mating were used as previously de-
scribed [10,34]. For the cranial irradiation experiments,
C57BL/6 N mice (5 weeks old) were purchased from the
Japan SLC (Hamamatsu, Japan) and habituated for over
one week before experimental procedures. All experimen-
tal procedures were approved by the Committee of Animal
Research of Kyoto University Faculty of Pharmaceutical
Sciences.
Cranial irradiation
Mice (6 weeks of age) were anesthetized by pentobar-
bital (50 mg/kg; Kyoritsu Pharma), and exposed to cra-
nial irradiation using a Rigaku Radiofrex 350 X-ray
generator operated at 250 kV and 15 mA with a 1-mm-
thick aluminum filter. X-rays at a dose of 10 Gy were de-
livered at a dose rate of 0.74 Gy/min. A lead shield was
placed over the body of the mice except the head. Non-
irradiated controls received anesthesia only. The fluoxet-
ine treatment was started 14 days after irradiation.
SSRI treatment
Fluoxetine hydrochloride (LKT laboratories, Inc., St.
Paul, MN, USA) was intraperitoneally injected for
21 days at a dose of 22 mg/kg. The fluoxetine solution
was prepared every day. Control mice were given saline.
For the comparison analysis of gene expression in the
DG (Figure 4D), 11 out of 21 mice were orally given
fluoxetine hydrochloride dissolved in 0.2% of saccharin
solution, which was applied for 28 days at a dose of
22 mg/kg. The concentration of fluoxetine was deter-
mined for individual mice based on the amount of liquid
consumption quantified during the preceding 24 h
period and the body weight [10]. Control mice were
given water (orally).
Measurement of tissue monoamine contents and in vivo
microdialysis
Measurement of tissue 5-HT and 5-HIAA contents were
performed as previously described with some modifica-
tions [35]. Briefly, 1-mm-thick coronal slices were
prepared using a brain matrix on ice. Then, tissue
blocks containing the dorsal raphe nucleus and me-
dian raphe nucleus or hippocampus were dissected,
homogenized, and sonicated in 300 μL of ice-cold
0.1 M HClO4 containing 10 mM Na2S2O5 and 1 mM
EDTA. Protein concentrations were measured by
using the Bradford protein assay (Bio-Rad, Hercules,
CA, USA). Homogenates were centrifuged at 16,000 × g
for 15 min at 4°C, and supernatants were stored at −80°C
until use. Supernatants were thawed on ice and ana-
lyzed by high-performance liquid chromatography with
an electrochemical detector (HPLC-ECD) (Eicom,
Kyoto, Japan). The measured 5-HT concentration was nor-
malized against the total protein concentration. The detec-
tion limits for both 5-HT and 5-HIAA were estimated to
be approximately 0.5–0.6 fmol per 25 μL of sample.
For in vivo microdialysis, mice were stereotactically
implanted with a guide cannula (Eicom) in the ventral
hippocampus according to the atlas of Franklin and
Paxinos [36] with the following coordinates: anterior-
posterior, −2.8 mm from the bregma; lateral, 3.0 mm
from the mid line; dorsal-ventral, −2.5 mm from the
skull surface. Experiments were performed 1 day after
surgery in awake and freely moving mice. On the day of
the experiment, a dialysis probe with a length of 1 mm
(Eicom) was inserted into the guide cannula and per-
fused with Ringer’s solution (147 mM NaCl, 4 mM KCl,
3 mM CaCl2) at a flow rate of 1 μL/min for 2–3 h. After
the initial perfusion period, dialysate samples were col-
lected every 20 min. On-line quantification of 5-HT in
the dialysate was accomplished by HPLC-ECD, and
seven basal samples were collected before administra-
tion. Fluoxetine (22 mg/kg) or saline was then adminis-
tered IP and samples were collected for an additional
120 min. The average values of the seven basal samples
for each animal were defined as 100% and used for
normalization. Probe placement in each mouse was his-
tologically verified by examining the coronal brain sec-
tions after completion of the experiment.
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Immunohistochemistry
On the day following the last treatment of fluoxetine,
mice intraperitoneally received BrdU (150 mg/kg, Sigma
B5002). Two hours after BrdU injection, the mice
were anesthetized by chloral hydrate (Nacalai Tesque,
Kyoto, Japan) and transcardially perfused with cold
saline followed by 4% paraformaldehyde (PFA) in
0.1 M phosphate buffer, pH 7.4. Brains were post-
fixed with 4% PFA overnight at 4°C, cryoprotected in
20% sucrose overnight, and stored at −80°C. Serial
sections were then cut through the entire hippocampus
[36] at a thickness of 30 μm with a cryostat (Leica
CM3050) and stored in a non-freezing solution at −20°C
until stained.
For BrdU immunostaining, every sixth section was
mounted on glass slides and incubated in 0.01 M citric
acid at 90°C for 5 min, denatured with 2 M hydrogen
chloride at 37°C for 30 min, neutralized with 0.1 M boric
acid (pH 8.5) at room temperature for 10 min, blocked
in 10% equine serum in PBS containing 0.3% Triton X-
100 at room temperature for 60 min, and incubated with
monoclonal rat anti-BrdU (1:200; Serotec OBT0030) at
room temperature overnight. For DCX and calbindin
immunostaining, sections were blocked in 10% equine
serum and incubated with polyclonal goat anti-DCX
(1:500; Santa Cruz SC8066) or monoclonal mouse anti-
calbindin D-28 K (1:3000; Sigma Aldrich, C9848). Sec-
tions were then incubated for 60 min with biotinylated
goat anti-rat IgG (1:1000; Vector BA9400) as the anti-
BrdU secondary antibody or biotinylated horse anti-goat
IgG (1:1000; Vector BA9500) as the anti-DCX secondary
antibody, or biotinylated horse anti-mouse IgG (1:1000;
Vector BA2000) as the calbindin D-28 K secondary anti-
body, followed by incubation with ABC Vectastain Kit
(Vector). Antigen detection was performed with 0.06%
3,3′-diaminobenzidine (DAB) staining and counterstain-
ing with Nuclear Fast Red (Vector).
For immunofluorescence staining, sections were
blocked in 10% equine serum and incubated overnight
at 4°C with polyclonal rabbit anti-β-galactosidase
(1:2000, MP, 55976) and either polyclonal goat anti-
DCX (1:500; Santa Cruz SC8066), monoclonal mouse
anti-calretinin (1:3000; Millipore, MAB 1568), monoclo-
nal mouse anti-NeuN (1:500; Millipore, MAB377), or
monoclonal mouse anti-calbindin D-28 K (1:3000; Sigma
Aldrich, C9848). Sections were then incubated for 60 min
with a secondary antibody conjugated with AlexaFluor 488
or AlexaFluor 555 (Molecular Probes).
Quantification of BrdU-labeled cells, DCX-positive cells,
and calbindin-IR
For BrdU-labeled cell quantification, a modified un-
biased stereological procedure was used as previously
described [37]. Sections were coded to ensure that the
analysis was performed by a blind observer using a light
microscope (Nikon Ecripse E200, Tokyo, Japan), and
BrdU-labeled cells in the SGZ of the hippocampus were
counted. Cells were included in SGZ counts if they were
touching the border between the GCL and the hilus, or
in the deepest layer of the GCL. If a cell was more than
two cell diameters from the GCL, it was excluded. Every
sixth 30-μm-thick section was evaluated throughout the
hippocampus, and the sum of the cell counts was
multiplied by six to provide an estimate of the total
number of BrdU-labeled cells in the entire region. For
DCX-positive cell quantification, 3–4 sections of the
DG were photographed using a Biozero BZ-8000
microscope (Keyence Corporation, Osaka, Japan) that
was fitted with a 20X objective. The boundaries of the
DG were set as regions of interest (ROI), and each
ROI was measured; then, DCX-positive cells were
manually counted within the ROI and their number
was expressed as the number of cells per square milli-
meter. For quantification of calbindin-IR, 2 sections of
the DG were photographed in the manner described
above. The pictures were converted into 16-bit gray
scale pictures and the average signal intensity of
calbindin-IR in the GCL region or ML region was
quantified by computer-assisted image analysis (ImageJ,
NIH, Bethesda, Maryland).
In situ hybridization
In situ hybridization was performed using a digoxigenin
(DIG)-labeled riboprobe as previously described [38]. A
Ht4r cDNA template probe was cloned by PCR with
gene-specific primers (Table 1), verified by sequencing,
and used to produce digoxigenin (DIG)-labeled ribo-
probes with the DIG RNA Labeling Kit (Roche,
Mannheim, Germany). Coronal brain sections (thickness,
10 μm) were cut on a cryostat, mounted onto slides,
fixed in 4% PFA, acetylated, and dehydrated prior to
hybridization. Sections were hybridized with the DIG-
labeled riboprobe. DIG was visualized using an alkaline
phosphatase-conjugated anti-DIG antibody and BM
purple substrate (Roche).
Table 1 List of primers used for quantitative real-time
PCR analysis and for the 5ht4r cDNA probe
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Quantitative RT-PCR
Total RNA was extracted from the DG using the
ReliaPrep RNA Miniprep System (Promega), and sub-
jected to reverse transcription with Superscript VILO
(Invitrogen), and followed by real-time PCR on a
LightCycler (Roche) using the Fast Start DNA Master
SYBR Green I (Roche). Expression levels of target
genes were normalized to the levels of 18S rRNA.
Primer sequences are shown in Table 1. The specifi-
city of each primer set was confirmed by checking
the product size by gel electrophoresis.
Statistical analyses
All data are presented as the mean ± S.E.M., and experi-
ments with 2 groups were compared using unpaired
Student’s t-test, whereas experiments with 4 groups
were subjected to two-way ANOVA, followed by the
Bonferroni post hoc test. A two-way repeated meas-
ure ANOVA was used for the microdialysis assay.
Significance marks in figures are based on results
from the t-test, two-way ANOVA test, and Bonferroni
post hoc tests. The threshold for statistical significance
was P < 0.05. All analyses were performed using PRISM 5
software (GraphPad, San Diego, CA).
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